Member Info for kitchens

another pharma i cant help it dyor

Nice to see some one is following progress here spend time talking to my self but they are working on a drug to combat that lol probably need a snippet of news to get a decent trading day in here 8 mill volume should do it for a proper squeeze on the shares which will force the price up KBC Aand CODE seem to be holding the bank but with so few shares in issue they will get down to empty and away we go patience as always

many thanks i do wonder what switched it on friday ? maybe some positive news on its way lets hope the volume keeps up and breaks thee mms a bit for a bit of stake building GL

any chance of a detailed chart view on this now please its posted a bull signal on ichiwith thin resistance at 2.7p thanks in advance

not realy punt money only company is crap never any news even if you mail them bunch of chancers running it depends how you view your losing money

solid rise here any news then ?

be a top up day if it dips

looking start to the day here 1.75 vs 2.25 still awaiting PR

but could be over next month ouch http://www.advfn.com/p.php?pid=nmona&cb=1244136704&article=38061917&symbol=L%5EXXIC

no move but a few more like it will move it

quiete here 1.75bid v 2.25 al mms

code selling at 6.75 on l2 incredible spead 3% ? go figure

We just need to finalise the deal with Crew, which is very imminent and we then expect to be in production this year. wouldnt that be nice :-)

important part of rns----both drugs in play so i guess the trial has thrown up a different use Notes for editors: About Minster Pharmaceuticals plc Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK. Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration. Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com. This information is provided by RNS

http://www.advfn.com/p.php?pid=nmona&cb=1243959168&article=38029542&symbol=L%5EMPM

do you think election results will have an effect here ?

lickle tick up heres hoping they open a little stronger tommorow

busy here today everyone must be on drugs

sell gone through with no downward movement lookin better

all info appreciated